Abstract
Background Proteome-wide association study (PWAS) integrating proteomic data with genome-wide association study (GWAS) summary data is a powerful tool for studying Alzheimer’s disease (AD) dementia. Existing PWAS analyses of AD often rely on the availability of individual-level proteomic and genetic data of a reference panel. Leveraging summary protein quantitative trait loci (pQTL) reference data of multiple AD-relevant tissues is expected to improve PWAS findings of AD dementia.
Methods We conducted PWAS of AD dementia by integrating publicly available summary pQTL data of brain, cerebrospinal fluid (CSF), and plasma tissues, with the latest GWAS summary data of AD dementia. For each target protein per tissue, we employed our recently published OTTERS tool to obtain omnibus PWAS p-value, to test whether the genetically regulated protein abundance in the corresponding tissue is associated with AD dementia. Protein-protein interactions and enriched pathways of identified significant PWAS risk genes were analyzed by STRING. The potential causal effects of these PWAS risk genes were assessed by probabilistic Mendelian randomization analyses.
Results We identified 30 unique significant PWAS risk genes for AD dementia, including 11 for brain, 9 for CSF, and 16 for plasma tissues. Four of these were shared by at least two tissues, and gene MAPK3 was found in all three tissues. We found that 11 of these PWAS risk genes were associated with AD or AD pathological hall marks as shown in GWAS Catalog; 18 of these were detected by transcriptome-wide association studies (TWAS); and 25 of these, including 8 out of 9 novel genes, were interconnected within a protein-protein interaction network involving the well-known AD risk gene APOE. Especially, these PWAS risk genes were enriched in immune response, glial cell proliferation, and high-density lipoprotein particle clearance pathways. Mediated causal effects were validated for 13 PWAS risk genes (43.3%).
Conclusions Our findings provide novel insights into the genetic mechanisms of AD dementia in brain, CSF, and plasma tissues, and targets for developing therapeutic interventions. We also demonstrated the effectiveness of integrating summary pQTL and GWAS data for mapping risk genes of complex human diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS, R35GM138313, for J.Y), and National Institute on Aging (NIA, AG071170, for M.P.E.). ROSMAP is supported by P30AG10161, P30AG72975, R01AG15819, R01AG17917, U01AG46152, and U01AG61356.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The source data were openly available before the initiation of the study. Summary-level pQTL data of brain, CSF, and plasma tissues can be accessed by emailing niagads{at}pennmedicine.upenn.edu to set up an FTP transfer of the data. OTTERS tool is available from https://github.com/daiqile96/OTTERS. PMR tool is available from https://github.com/yuanzhongshang/PMR. The code used in this study for conducting PWAS of AD dementia are available from GitHub https://github.com/tingyhu45/PWAS_OTTERS. Trained pQTL weights by five PRS methods and our PWAS summary data will be deposited to SYNAPSE once this work is accepted. ROSMAP data can be requested at www.radc.rush.edu and www.synapse.org.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵+ Co-first authors.
We used the most recent 2022 GWAS summary data of AD in this manuscript.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
List of Abbreviations
- PWAS
- Proteome-wide association study
- GWAS
- Genome-wide association study
- AD
- Alzheimer’s disease
- pQTL
- Protein quantitative trait loci
- CSF
- Cerebrospinal fluid
- PRS
- Polygenic risk score
- ACAT
- Aggregated Cauchy association test
- PPI
- Protein-protein interaction
- PMR-Egger
- Probabilistic Mendelian randomization Egger
- TWAS
- Transcriptome-wide association study
- DLPFC
- Dorsolateral prefrontal cortex
- WGS
- Whole genome sequencing
- proxy-ADD
- proxy AD and related dementia
- UKBB
- UK Biobank
- LD
- Linkage disequilibrium
- FDR
- False discovery rate
- ROS/MAP
- Religious Orders Study and Memory and Aging Project
- GO
- Gene Ontologies
- MAF
- Minor allele frequency
- TPM
- Transcripts per million
- PEER
- Probabilistic estimation of expression residuals